市場調查報告書

克隆氏症診斷及治療的全球市場:成長,趨勢與預測(2017年∼2022年)

Crohn's Disease Diagnostic and Therapeutic Market

出版商 Mordor Intelligence LLP 商品編碼 391371
出版日期 內容資訊 英文 113 Pages
商品交期: 2-3個工作天內
價格
克隆氏症診斷及治療的全球市場:成長,趨勢與預測(2017年∼2022年) Crohn's Disease Diagnostic and Therapeutic Market
出版日期: 2019年05月01日內容資訊: 英文 113 Pages
簡介

克隆氏症(CD)是一種炎症性腸病(IBD),影響從口腔到肛門的胃腸道的任何部分。由於遺傳易感人群中的環境因素,免疫因素和細菌因素共同造成的。據亞特蘭大CDS估計,每10萬人中約有200人受到影響,發病率為每10萬人每年3.1至14.6人。

本報告提供全球克隆氏症診斷及治療市場調查,整體市場趨勢,各產品、地區的詳細趨勢,市場成長的影響要素分析,競爭情形,主要企業簡介等,總括性彙整。

目錄

第1章 簡介

  • 調查的成果
  • 市場定義
  • 數量單位
  • 基本貨幣
  • 檢討與預測期間
  • 一般調查的前提條件

第2章 調查方法

  • 簡介
  • 分析方法論
  • 計量預測模式
  • 調查的前提條件

第3章 摘要整理

第4章 關鍵問題

第5章 市場概況及產業的趨勢

  • 目前市場方案
  • 技術概要
  • 治療藥新的發展
  • 投資分析
  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 競爭程度
    • 替代品的威脅
    • 新加入廠商的威脅

第6章 成長要素,阻礙因素,機會及課題分析(DROC)

  • 市場成長要素
    • 這個疾病相關的複數的症狀,必須在個別治療上注意
    • 迅速的診斷的要求
    • 受影響人口隨著時間而增加
  • 市場阻礙因素
    • 市場上沒有可取得的特定治療藥
    • 人們的意識缺乏及與其他腸胃疾病的症狀相似性
    • 缺乏成本效果高的治療方法
  • 市場機會
    • 生物相似藥的出現
    • 抗TNF市售品牌Remicade和Humira等各種有用藥物的專利到期

新參與市場企業的大門

  • 主要課題

第7章 全球克隆氏症診斷及治療市場

  • 回結腸炎
  • 髂骨炎
  • 胃十二指腸的克隆氏症
  • 空腸回腸炎
  • 克隆結腸炎

第8章 全球克隆氏症的診斷及治療市場:各診斷方法

  • 血液檢驗
  • 糞便檢驗
  • 大腸內視鏡檢驗
  • 彈性S狀結腸鏡檢驗
  • 電腦斷層攝影
  • 磁振造影
  • 膠囊內視鏡
  • 雙球囊內視鏡檢驗

第9章 克隆氏症的診斷及治療市場:各治療法

  • 藥、投藥
    • 發炎治療藥
    • 免疫抑劑
    • 止痛藥
  • 手術

第10章 全球克隆氏症診斷及治療市場:各地區(市場佔有率與預測)

  • 北美
    • 簡介
    • 美國
    • 加拿大
    • 其他
  • 歐洲
    • 簡介
    • 法國
    • 英國
    • 德國
    • 西班牙
    • 俄羅斯
    • 義大利
    • 其他
  • 亞太地區
    • 簡介
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 其他
  • 中東、非洲
    • 簡介
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 以色列
    • 其他MEA各國
  • 中南美
    • 簡介
    • 巴西
    • 墨西哥
    • 阿根廷
    • 其他

第11章 競爭情形

第12章 主要供應商

  • Abbvie
  • Celgene Corportation
  • Genetech
  • Janssen Biotech Inc.
  • Pfizer Inc.
  • Prometheus Laboratories Inc.
  • Salix Pharmaceuticals Inc.
  • 武田藥品工業
  • Johnnson and Johnnson

第13章 投資機會的分析師預期

第14章 市場未來展望

第8章 附錄

  • 簡稱
  • 參考文獻
  • 免責聲明

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 50777

Market Overview

The global Crohn's disease diagnostic and therapeutics market is estimated to grow at a CAGR of 3.1% during the forecast period. Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.

Increasing awareness of the Crohn's disease, coupled with rising initiatives by regulatory bodies for the development of novel treatment options, is expected to provide the market with high growth potential.

Scope of the Report

Crohn's disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals.

Key Market Trends

On the basis of Therapeutics, Anti-Inflammatory agents led the global market in 2018

Anti-inflammatory agents continued to lead as the largest sub-segment unde the Therapeutics segment of the market in 2018 due to its higher efficacy, compared to immunosuppressant and analgesic, while immune system suppressors is expected to be the fastest-growing segment owing to a reduction in surgeries and hospitalization rates.

A specific category of anti-inflammatory agents includes Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of Crohn's disease.

North America Holds the Largest Market Share

North America has held the largest market share in the Crohn's disease diagnostic and therapeutic market due to the increasing prevalence of Crohn's disease in the region. Additionally, the Asia-Pacific region is expected to register high growth during the forecast period.

According to the Center for the Disease Control and Prevention (CDC), in the United States, it is currently estimated that about 1.3 million people suffer from inflammatory bowel disorder (IBD). The IBD prevalence includes prevalence for ulcerative colitis (UC) and Crohn's disease. In this region, urbanization is a potential contributing factor for the increasing prevalence of Crohn's disease. The incidence of CD is attributed to the result of "westernization" of lifestyle, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals.

Overall, the Crohn's disease has been shown to affect North American and Western European countries more heavily than others, with more than 750,000 people living with Crohn's disease in the United States alone.

Competitive Landscape

Crohns disease diagnostic and therapeutic market has growing opportunities both in the developing and nations of the world. However US region controls the majority of market share which can be attributed to the higher prices of pharmaceuticals and the greater diagnosed prevalence of Crohn's disease in the region as well as the high annual cost of therapy (ACOT) of Stelara (Johnson & Johnson) and the ACOT of Risankizumab (AbbVie) in the US market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
    • 4.2.2 Demand for Prompt Diagnosis
    • 4.2.3 Affected Population Increasing with Time
  • 4.3 Market Restraints
    • 4.3.1 No Specific Treatment or Drug Available in the Market
    • 4.3.2 Lack of Awareness Among the People and Symptom Similarity with Other Gastrointestinal Disease
    • 4.3.3 Lack of a Cost Effective Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Diagnostics
    • 5.1.1 Blood Test
    • 5.1.2 Fecal Test
    • 5.1.3 Colonoscopy
    • 5.1.4 Flexible Sigmoidoscopy
    • 5.1.5 Computerised Tomography
    • 5.1.6 Magnetic Resonance Imaging
    • 5.1.7 Others (Capsule Endoscopy etc)
  • 5.2 Treatment
    • 5.2.1 Medication
      • 5.2.1.1 Anti-Inflammatory Agents
      • 5.2.1.2 Immunosuppressants
      • 5.2.1.3 Analgesics & Anti-Pyretics
    • 5.2.2 Surgery
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc
    • 6.1.2 Celgene Corporation
    • 6.1.3 Genetech
    • 6.1.4 Janssen Biotech Inc.
    • 6.1.5 Johnson & Johnson
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Prometheus Laboratories Inc. (Nestle)
    • 6.1.8 Salix Pharmaceuticals Inc.(Valeant Pharmaceuticals)
    • 6.1.9 Takeda's Pharmaceutical Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS